StockData
UNITED THERAPEUTICS Corp logo

UNITED THERAPEUTICS Corp (UTHR) stock

UTHRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 11/3022% above fair value
$577.34−6.76 (-1.16%)

Close on Nov 18, 2026Market cap $24.76BP/E 20.7Yield –

United Therapeutics revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

United Therapeutics's revenue for the twelve months ending Jun 30, 2026 was $3.15B, up 2.5% year over year. For fiscal 2025 it was $3.18B, up 10.6% from the year before. Over ten years it grew 8.1% a year on average. The highest annual figure on record is $3.18B in fiscal 2025.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$3.18B+10.6%
FY2024Dec 31, 2024$2.88B+23.6%
FY2023Dec 31, 2023$2.33B+20.2%
FY2022Dec 31, 2022$1.94B+14.9%
FY2021Dec 31, 2021$1.69B+13.6%
FY2020Dec 31, 2020$1.48B+2.4%
FY2019Dec 31, 2019$1.45B-11.0%
FY2018Dec 31, 2018$1.63B-5.7%
FY2017Dec 31, 2017$1.73B+7.9%
FY2016Dec 31, 2016$1.60B+9.1%
FY2015Dec 31, 2015$1.47B+13.8%
FY2014Dec 31, 2014$1.29B+15.4%
FY2013Dec 31, 2013$1.12B+21.9%
FY2012Dec 31, 2012$916.08M+23.3%
FY2011Dec 31, 2011$743.18M+25.3%
FY2010Dec 31, 2010$592.90M+65.2%
FY2009Dec 31, 2009$358.88M+27.5%
FY2008Dec 31, 2008$281.50M–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$783.30M-1.9%
Q1 FY2026Mar 31, 2026$781.50M-1.6%
Q4 FY2025Dec 31, 2025$790.20M+7.4%
Q3 FY2025Sep 30, 2025$799.50M+6.8%
Q2 FY2025Jun 30, 2025$798.60M+11.7%
Q1 FY2025Mar 31, 2025$794.40M+17.2%
Q4 FY2024Dec 31, 2024$735.90M+19.7%
Q3 FY2024Sep 30, 2024$748.90M+22.9%
Q2 FY2024Jun 30, 2024$714.90M+19.8%
Q1 FY2024Mar 31, 2024$677.70M+33.7%
Q4 FY2023Dec 31, 2023$614.70M+25.1%
Q3 FY2023Sep 30, 2023$609.40M+18.1%
Q2 FY2023Jun 30, 2023$596.50M+27.8%
Q1 FY2023Mar 31, 2023$506.90M+9.7%
Q4 FY2022Dec 31, 2022$491.50M+18.4%
Q3 FY2022Sep 30, 2022$516.00M+16.0%
Q2 FY2022Jun 30, 2022$466.90M+4.6%
Q1 FY2022Mar 31, 2022$461.90M+21.8%
Q4 FY2021Dec 31, 2021$415.20M+7.9%
Q3 FY2021Sep 30, 2021$444.70M+17.0%
Q2 FY2021Jun 30, 2021$446.50M+23.3%
Q1 FY2021Mar 31, 2021$379.10M+6.4%
Q4 FY2020Dec 31, 2020$384.90M+23.7%
Q3 FY2020Sep 30, 2020$380.10M-5.3%
Q2 FY2020Jun 30, 2020$362.00M-3.1%
Q1 FY2020Mar 31, 2020$356.30M-1.7%
Q4 FY2019Dec 31, 2019$311.10M-18.4%
Q3 FY2019Sep 30, 2019$401.50M-2.7%
Q2 FY2019Jun 30, 2019$373.60M-16.0%
Q1 FY2019Mar 31, 2019$362.60M-6.8%
Q4 FY2018Dec 31, 2018$381.40M-17.9%
Q3 FY2018Sep 30, 2018$412.70M-7.4%
Q2 FY2018Jun 30, 2018$444.50M-0.0%
Q1 FY2018Mar 31, 2018$389.20M+5.0%
Q4 FY2017Dec 31, 2017$464.70M+13.6%
Q3 FY2017Sep 30, 2017$445.50M+9.1%
Q2 FY2017Jun 30, 2017$444.60M–
Q1 FY2017Mar 31, 2017$370.50M–
Q4 FY2016Dec 31, 2016$409.00M–
Q3 FY2016Sep 30, 2016$408.20M–

More United Therapeutics figures

See a number that looks wrong?